<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467517</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0235</org_study_id>
    <nct_id>NCT02467517</nct_id>
  </id_info>
  <brief_title>Ketamine and Neuropathic Pain</brief_title>
  <acronym>KETAPAIN</acronym>
  <official_title>Ketamine and Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The primary outcome is to compare the analgesic efficacy of intravenous ketamine treatment to&#xD;
      that of a placebo in patients with refractory neuropathic pain.&#xD;
&#xD;
      The secondary outcomes are:&#xD;
&#xD;
        1. - To compare the additive analgesic efficacy of prior administration of magnesium&#xD;
           sulfate to that of placebo and ketamine only, on the effectiveness of intravenous&#xD;
           ketamine treatment,&#xD;
&#xD;
        2. - To study the evolution time of pain and analgesia after the intravenous administration&#xD;
           of ketamine and placebo,&#xD;
&#xD;
        3. - To study the correlation of the analgesic response to administered products&#xD;
           respectively ketamine, ketamine and magnesium sulfate, placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of the study:&#xD;
&#xD;
      Single-center clinical trial, controlled, randomized, double-blind, crossover design, against&#xD;
      inactive placebo.&#xD;
&#xD;
      Each patient will receive successively the 3 products (ketamine / placebo, ketamine /&#xD;
      magnesium sulfate, placebo / placebo) follows a predeter randomization list, with a wash-out&#xD;
      period between each administration.&#xD;
&#xD;
      Visit 1&#xD;
&#xD;
      -Inclusion visit, signature of informed consent form, clinical examination and fill&#xD;
      questionnaires.&#xD;
&#xD;
      For women of childbearing age a pregnancy test will be performed.The pain will be measured by&#xD;
      a numerical scale.&#xD;
&#xD;
      The pain will be evaluated by scoring on a numerical scale. A booklet for monitoring&#xD;
      analgesic concomitant medication and overall pain on a numerical scale will be given to the&#xD;
      patient 14 days before the programmed infusion.&#xD;
&#xD;
      Visit 2 : Period 1 Day 0&#xD;
&#xD;
      Clinical examination, return of booklet completed by patient and fill questionnaires.&#xD;
&#xD;
      The pain will be evaluated by scoring on a numerical scale before and after the infusion.&#xD;
&#xD;
      For women of childbearing age a pregnancy test will be performed. Treatment allocation period&#xD;
      follows a predeter randomization list. At the end of the infusion, a booklet for monitoring&#xD;
      will be given to patients for the following weeks in order to score their overall pain until&#xD;
      the next study period.&#xD;
&#xD;
      The output of the hospital patient (CPC / CETD) after each treatment will be authorized by&#xD;
      the investigator.&#xD;
&#xD;
      Wash-out period: 5 weeks.&#xD;
&#xD;
      Phone call 1 (Day 1):&#xD;
&#xD;
      Patients will be called by phone to collect adverse events and concomitant medications. If&#xD;
      necessary, the patients should return to consult the CPC / CETD for a clinical examination.&#xD;
&#xD;
      Patients will be called the week before their scheduled visit, if at that time their&#xD;
      spontaneous pain is still low, according to the opinion of the investigator, the infusion&#xD;
      visit will be shifted to allow the pain level back its basal level.&#xD;
&#xD;
      Visit 3 : Period 2 : Day 36 +/- 3 days&#xD;
&#xD;
      Same of period 1.&#xD;
&#xD;
      Phone call 2 J 37 +/- 3 days:&#xD;
&#xD;
      Same of phone call 1.&#xD;
&#xD;
      Visit 4 : Period 3 : Day 72 +/- 3 days&#xD;
&#xD;
      Same of period 1&#xD;
&#xD;
      Phone call 3 J 73 +/- 3 days:&#xD;
&#xD;
      Same of phone call 1.&#xD;
&#xD;
      Visit 5 : Day 108 +/- 3 days&#xD;
&#xD;
      Clinical examination, return of booklet completed by patient and fill questionnaires.&#xD;
&#xD;
      The pain will be evaluated by scoring on a numerical scale For women of childbearing age a&#xD;
      pregnancy test will be performed. This visit is the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical rating scale (NRS)</measure>
    <time_frame>at day 1 and for a period of 5 weeks (35 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of the average</measure>
    <time_frame>at day 1</time_frame>
    <description>Intensity of the average daily pain evaluated by a numerical rating scale (NRS) assessed using a booklet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of maximum daily pain</measure>
    <time_frame>at day 1</time_frame>
    <description>Intensity of maximum daily pain evaluated by a numerical rating scale (NRS) assessed using a booklet,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on quality of life</measure>
    <time_frame>at day 1</time_frame>
    <description>Impact on quality of life, mood and sleep assessed by questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on mood</measure>
    <time_frame>at day 1</time_frame>
    <description>Impact on quality of life, mood and sleep assessed by questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on sleep</measure>
    <time_frame>at day 1</time_frame>
    <description>Impact on quality of life, mood and sleep assessed by questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>INTRAVENOUS KETAMINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>INTRAVENOUS KETAMINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <arm_group_label>INTRAVENOUS KETAMINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo : sodium chloride</intervention_name>
    <arm_group_label>INTRAVENOUS KETAMINE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient (s) are at least18 years old, with chronic pain (for more than 3 months),&#xD;
             having the characteristics of a peripheral or central neuropathy, follow (s) at the&#xD;
             Pain Clinic CHU Clermont-Ferrand and justifying the establishment of a therapeutic&#xD;
             program including intravenous infusion of ketamine (as therapeutic test);&#xD;
&#xD;
          -  Patient (s) who had never received ketamine infusion under the care of their&#xD;
             neuropathic pain;&#xD;
&#xD;
          -  History of illness compatible with an injury or disease of the somatosensory system;&#xD;
&#xD;
          -  Localized pain in an anatomical neuro territory;&#xD;
&#xD;
          -  Neurological examination shows sensory abnormalities,&#xD;
&#xD;
          -  The patients of childbearing potential must use effective contraception throughout the&#xD;
             study;&#xD;
&#xD;
          -  For womens of childbearing age, they will be enrolled in the study after a negative&#xD;
             urine pregnancy test; in case of suspicion of pregnancy, a blood pregnancy test should&#xD;
             be performed;&#xD;
&#xD;
          -  Cooperation and willing to follow the study;&#xD;
&#xD;
          -  Acceptance to give written consent;&#xD;
&#xD;
          -  Affiliated to the French social security;&#xD;
&#xD;
          -  Inscription or acceptation of inscription in the national register of volunteers&#xD;
             involved in trials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient (s) who have received intravenous ketamine infusion;&#xD;
&#xD;
          -  Patients with one or many contraindication to ketamine administration: known&#xD;
             hypersensitivity to ketamine in which one of the constituents of the product,&#xD;
             uncontrolled high blood pressure, severe cardiac insufficiency;&#xD;
&#xD;
          -  Patients with one or many contraindication of magnesium sulfate administration:&#xD;
             Patients with severe renal impairment;&#xD;
&#xD;
          -  Patients with one or many contraindication to administration of sodium chloride: water&#xD;
             inflation, fluid retention;&#xD;
&#xD;
          -  Patients with a medical history and / or surgical judged by the investigator to be not&#xD;
             consistent with the clinical trial;&#xD;
&#xD;
          -  Patients with drug treatments judged by the investigator to be not consistent with the&#xD;
             clinical trial;&#xD;
&#xD;
          -  Pregnancy or lactation women;&#xD;
&#xD;
          -  Patient who participated in another clinical trial, located in exclusion period or&#xD;
             received benefits &gt; 4500 euros during 12 months before the beginning of trial;&#xD;
&#xD;
          -  Patients with cooperation and understanding not to adhere strictly to the conditions&#xD;
             provided in the clinical trial;&#xD;
&#xD;
          -  Patients receiving a measure of legal protection (guardianship…);&#xD;
&#xD;
          -  Patients are not affiliated to the System of the French Social Security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisèle PICKERING</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Noémie DELAGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale PICARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne MARCAILLOU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude DUBRAY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian DUALE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic pain</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Magnesium sulfate</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Anxiety and depression</keyword>
  <keyword>Mood and sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

